Why it matters
AI is becoming embedded across regulated product development rather than remaining a separate digital-health category.
Decision implication
Track where FDA expectations become more explicit by phase and build those requirements into evidence/adoption readiness for AI-enabled life-science products.
Who or what is affected
- FDA CDER
- biopharma
- AI developers
- clinical-research organizations
Evidence and sources
E5 — official FDA source
P4L distinguishes the sourced event from the interpretation above. Participation, funding, proposed policy, or program inclusion does not by itself establish clinical effectiveness.
What P4L is watching next
- Guidance
- submission examples
- validation expectations
- postmarket use.